Critical Path Institute (C-Path)
Daniel Jorgensen, MD, MPH, MBA, is an accomplished leader in the healthcare and pharmaceutical industries, currently serving as Chief Executive Officer of the Critical Path Institute since October 2022. Previous roles include Chief Executive Officer at AxoProtego Therapeutics and Chief Medical Officer positions at Ocugen, Crestovo, and Cellceutix Corporation. Daniel has extensive experience in clinical development and research, having held significant roles at PolyMedix, AMAG Pharmaceuticals, and Pfizer, where responsibilities included senior leadership in global research and development. Daniel's educational background includes advanced degrees in medicine and public health from esteemed institutions such as Emory University and the University of Washington, complemented by an MBA from Yale University.
This person is not in any offices
Critical Path Institute (C-Path)
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.